3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Carcinoma, Renal Cell
29
Carcinoma, Hepatocellular
16
Prostatic Neoplasms
12
Neoplasm Metastasis
11
Carcinoma, Non-Small-Cell Lung
9
Neoplasms
8
Sarcoma
7
Osteosarcoma
6
Neuroendocrine Tumors
6
Brain Neoplasms
6
Urinary Bladder Neoplasms
5
Kidney Neoplasms
5
Carcinoma, Transitional Cell
5
Breast Neoplasms
5
Sarcoma, Ewing
4
Melanoma
4
Lung Neoplasms
4
Recurrence
3
Pancreatic Neoplasms
3
Ovarian Neoplasms
3
Clear-cell metastatic renal cell carcinoma
3
Carcinoid Tumor
3
Adrenocortical Carcinoma
3
Adenocarcinoma
3
Wilms Tumor
2
Uterine Cervical Neoplasms
2
Urethral Neoplasms
2
Thyroid Neoplasms
2
Thyroid Diseases
2
Thyroid Cancer, Papillary
2
Interventions
lutetium Lu 177 dotatate
2
copper dotatate CU-64
2
Etoposide
2
zimberelimab
1
folfirinox
1
famitinib
1
cabozantinib
1
abemaciclib
1
Temozolomide
1
Nivolumab
1
Lutetium-177
1
Lutetium
1
Irinotecan
1
Granulocyte Colony-Stimulating Factor
1
Fluorodeoxyglucose F18
1
Filgrastim
1
Cytokines
1
Cryotherapy
1
Copper
1
Cisplatin
1
Carboplatin
1
Acupuncture Therapy
1
Acupressure
1
64Cu-DOTATATE
1
177Lu-octreotide, DOTA(0)-Tyr(3)-
1
11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo(5,4-a)pyrrolo(3,4-c)carbazol-4-one
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Gastro-enteropancreatic neuroendocrine tumor
×
cabozantinib
×
Clear all
NCT04893785
2024-06-18
CABOTEM
National Cancer Institute, Naples
Phase 2
Recruiting
35 enrolled